2014 will be a make or break for OXGN. Only $7 million left in the nest egg. They will have to go for more funding in order to stay afloat. People buy these bio companies on hope they'll develop something promising. It's the same kind of hope that your lottery ticket will be a winner.
You might want to read the 8K filed on March 18. They had 25M in cash with a burn of around 2M/quarter. Per the 8K they had $16.2M as of Feb 28 and received an additional $9.3M through March 17 from warrants.